Structural analysis of the herpes simplex virus polymerase revealed that mutations affecting its drug binding and flexibility may drive treatment resistance.
Scientists discovered a long sought-after inhibitor for the DNA repair polymerase, Polθ, which may be key to treating drug-resistant BRCA1 and BRCA2-mutant cancers.